Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Sign Up to like & getrecommendations! Published in 2018 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2018.01.011
Abstract: Leiomyosarcomas (LMS) are rare tumors with poor prognosis owing to the high rate of recurrent and metastatic disease. The combination of doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM) results in moderate response rates of 10%-30%.… read more here.
Keywords: doxorubicin treatment; treatment; treatment advanced; aim regimen ... See more keywords
Therapeutic advances in leiomyosarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1149106
Abstract: Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the most common subtypes of soft tissue sarcomas. It is characterized by significant disease heterogeneity with variable sites of origin and diverse genomic profiles. As… read more here.
Keywords: advanced leiomyosarcoma; therapeutic advances; leiomyosarcoma; advances leiomyosarcoma ... See more keywords